Neoprobe to submit phase II/III Lymphoseek trial data to FDA:
This article was originally published in Clinica
Executive Summary
After meeting the primary endpoint in a phase II clinical trial of its Lymphoseek tracer, Neoprobe is preparing to submit both phase II and phase III clinical trials data to the US FDA. The primary endpoint in the phase II trial was for Lymphoseek (Technetium Tc99m DTPA-mannosyl-dextran) to achieve 90% localisation to lymphoid tissue - localisation was reported in 94% of the procedures performed during the study, which was carried out in breast cancer and melanoma patients. Neoprobe, based in Dublin, Ohio, now plans to begin "winding down" its phase II trial activities, collecting 30-day patient safety follow-up information and accumulating data to report to the agency. Lymphoseek is a radioactive targeting agent developed for use with handheld gamma detection devices, such as Neoprobe's neo2000 system, during the surgical procedure, sentinel lymph node biopsy (SLNB).
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.